Thymulin: a real thymus hormone with almost no treatment trials in people

Thymulin is a genuine human hormone: a nine-amino-acid peptide made by the thymus, active only when it carries a zinc atom. Researchers have measured it in human blood for nearly 50 years, and its levels track zinc status, age and thymus recovery. What is missing is evidence that giving thymulin to people does anything. The only human treatment study we found is an open trial from 1987 whose results we couldn’t access, and the case for it as a therapy rests on rodent work.

What it is

In 1977 Jean-François Bach’s group isolated a “circulating thymic factor” (facteur thymique sérique, FTS) from about 1,000 litres of pig serum [1] and worked out its sequence: pyroglutamate, alanine, lysine, serine, glutamine, glycine, glycine, serine and asparagine [2]. A synthetic copy behaved like the natural peptide [2]. Later work showed the peptide only works when bound to one zinc ion, which gives it a specific folded shape, and it was renamed thymulin [3]. The thymic epithelial cells that make it contain zinc, suggesting it leaves the gland in its active form [3].

Its proposed job is helping T cells mature, both inside the thymus and outside it [3]. Rodent studies add anti-inflammatory effects and links to the pituitary gland. Those roles are described below and remain mechanism theory for humans.

Watch the names. Thymulin is not thymalin, the thymus extract used in Russian ageing studies, and it is not thymosin alpha-1 or thymosin beta-4, which are different thymus peptides with their own evidence [9]. Online sources mix them up often.

The human evidence

What people have been measured for

Most human thymulin research uses it as a marker rather than a treatment, and that work is solid enough to be useful.

Zinc deficiency. In a 1988 study in the Journal of Clinical Investigation, Ananda Prasad’s group induced mild zinc deficiency in two volunteers through diet and also studied six adults with sickle cell anaemia and six others with mild zinc deficiency [4]. Blood thymulin activity fell with zinc deficiency and recovered when zinc was restored, both in the body and when zinc was added to samples in the lab [4]. Changes in T-cell subsets moved in step. The authors proposed thymulin activity as a sensitive sign of mild zinc deficiency.

Zinc supplements in Crohn’s disease. Twenty-seven people with Crohn’s disease in remission, who had low zinc and thymulin, were randomised to 60 mg or 200 mg of zinc sulphate a day or placebo for three months [5]. Only the higher zinc dose raised thymulin activity; lymphocyte counts didn’t change [5]. The point for readers: in this trial, zinc raised the body’s own thymulin.

Ageing. In a 1996 comparison of young donors, healthy older people and people with Alzheimer’s-type dementia, thymulin activity was highest in the young and lowest in dementia [6]. Adding zinc to the samples brought activity in the older groups up to young levels, which suggests much of the age-related drop reflects too little zinc on the peptide rather than too little peptide [6].

Thymus recovery after transplant. In 21 infants with life-threatening combined immunodeficiency disorders given bone marrow transplants, 20 had undetectable or low thymulin before transplant [7]. After it, thymulin appeared in 17 of 18 evaluable children, and in every child who recovered immune function, the thymulin rise came first [7].

Zinc and age, in larger groups. One research group measured active thymulin in 19 people on dialysis, 58 with prolactin-secreting pituitary tumours and 41 with acromegaly [14]. The authors describe active thymulin as declining progressively from the age of 10 to 20 years. Levels were low in the dialysis and prolactinoma groups, where zinc was low, and high in acromegaly, where zinc was high. Six months of oral zinc sulphate raised both zinc and active thymulin in the low groups regardless of age [14]. The authors read this as zinc overriding the effect of age on thymulin output.

When zinc isn’t the whole story. In five children with Down’s syndrome and recurrent infections, all had low thymulin; four of the five stayed low even with normal or restored cellular zinc [15]. The authors suspected a fault in the thymus itself. It is a tiny retrospective series, but a useful counterweight to the idea that zinc explains everything.

Thymulin given as a treatment

This is where the record runs out. We found one human treatment study: an open-label trial of thymulin (FTS-Zn) in rheumatoid arthritis, published in 1987 with clinical and immune follow-up [8]. It has no abstract in PubMed and we couldn’t access the full text, so we can’t report its size or results. A recent review of thymic hormones surveys clinical applications across the whole family of thymic peptides [9]; for thymulin itself, we found no human treatment trial beyond the 1987 study. We found no registered modern trial of thymulin in people.

Why a good marker isn’t a treatment case

Marketing for thymulin tends to borrow the credibility of the measurement studies. The logic runs: thymulin falls with age, low thymulin goes with weaker immunity, so topping it up should help. Each step sounds reasonable, and none has been tested in a trial. The human studies above show thymulin rising and falling with zinc, age and thymus health. They don’t show that adding the peptide from outside restores any of those things, and in most of them the lever that moved thymulin was zinc [4,5,14]. A falling marker can be a consequence of an ageing thymus rather than a cause of anything downstream.

What the animal and lab work suggests

The preclinical work is broader and consistent in direction, but all of it is in rodents or cells.

• Diabetes in mice. In mice with chemically induced type 1 diabetes, thymulin reduced the physical impairments the researchers measured, such as changes in blood glucose and body weight, and lowered inflammatory signals including TNF-alpha and interferon-gamma [10].
• Inflammatory pain in rats. In rats with adjuvant-induced paw inflammation, thymulin reduced heat sensitivity and swelling and calmed immune cells in the spinal cord [11].
• Lung disease models. A 2010 review of rodent lung injury studies described thymulin suppressing inflammatory signalling and noted no toxicity even at high doses in those models [13].
• Ageing and the pituitary. Researchers used gene therapy to make muscle in thymus-deficient and old rodents produce thymulin continuously; restoring blood thymulin corrected some pituitary hormone abnormalities [12]. That is a gene therapy result, not a result for injected peptide.

Safety and side effects reported

There is no meaningful human safety record for thymulin given as a drug. The 1987 arthritis trial [8] is too obscure to draw on. The rodent lung review reported no toxicity at high doses [13], which says little about repeated use in people. Because thymulin’s activity depends on zinc, anyone reading about it should know the only randomised human data we found show zinc, not thymulin, restoring its levels [5].

Legal and regulatory status

Thymulin is not approved as a medicine in the UK, the US or the EU, and we found no marketing authorisation for it anywhere. It isn’t named on the WADA Prohibited List; as a substance without approval for human therapeutic use, it would fall under WADA’s S0 category for athletes.

What we still don’t know

• Whether giving thymulin to adults does anything to immune function, inflammation or ageing.
• Whether low thymulin in older people is best fixed by correcting zinc rather than by adding the peptide.
• How injected thymulin behaves in the human body, and whether it loads with zinc once there.
• What the 1987 rheumatoid arthritis trial found.
• Whether synthetic thymulin sold outside clinical settings carries its zinc and is what the label says.

Educational content only — not medical advice. Many peptides discussed on HPR are not approved for human use. Talk to a qualified clinician before making any decision about your health.

Free live webinar · Thursday 1 October · 7pm UK time

Join the next webinar: Introduction to Peptides

with Mitch O’Callaghan, ISSCA Peptide Therapist · Founder, Proper Protocols

Save my free placeHPR × Proper Protocols · Free · live online · with Q&A